This week’s headlines include: Older women are being significantly shortchanged by medical research, Expanded solutions for seamless stem cell research, Hope, despair and CRISPR — the race to save one woman’s life, Sanofi heads out to surf Belharra in $700M biobucks immunology deal, and US FDA approves Merck’s pneumococcal vaccine for adults.

Podcasts:

Check out our podcast channel. We have over 100 great podcasts covering drug discovery, stem cell culture, upstream and downstream biomanufacturing and more! Click below to download from iTunes or Google play:

Check out Eppendorf’s bioprocessing solutions for modern food production. Modern food is a very interesting area to explore in bioprocessing!

Eppendorf is dedicated to paving your path to new ways of food bioprocessing. Emerging production technologies offer more plant-based and animal-free food alternatives that promise to reduce the issues related to livestock – from deforestation to microbial antibiotic resistances, and concerns regarding poor animal welfare.

Whether it is the creation of cultured meat from stem cells, or the production of modern food using fermentation, we aim to help you bring your bioprocesses to the next level.

Learn More at Lab Academy

In Case You Missed It, Recent Articles on Cell Culture Dish and Downstream Column:

Streamlining Clone Cell Line Development Workflows

Cell line development (CLD) is the process of creating genetically engineered cells that stably produce a specific protein or biomolecule of interest, primarily for use in research, biopharmaceutical production, and therapeutic applications. This critical process involves the selection, modification, and expansion of host cells to ensure consistent and high-yield production of biologically active proteins…

Ask the Expert – Automating Cell Line Development Workflows

Automation addresses key challenges in manual cell line development (CLD) workflows such as ensuring clonality and maintaining data traceability and integrity. These issues can be particularly difficult in manual workflows where errors can occur, but automation helps streamline these processes, enhancing reproducibility and reliability…

Pioneering Access and Innovation: The Future of Cell and Gene Therapies

In this podcast, we spoke with Fran Gregory, Vice President of Emerging Therapies at Cardinal Health about the cell and gene therapy landscape, innovative solutions to reduce cost, the regulatory environment, and reimbursement…

Employing Automation to Speed Cell Line Development

Mammalian cell line development is essential in the biopharmaceutical industry for applications such as vaccines, therapeutic proteins, recombinant therapies, and drug screening. Traditionally, this process has been manual, requiring months of repetitive, meticulous work prone to human error and contamination. With the growing demand for biotherapeutics, especially monoclonal antibodies, these lengthy development cycles can no longer keep pace…

Getting the Most From Inline Buffer Formulation: MOTIV^® Performance Data Review

In this mini-webinar Nainesh Shah, Sr. Application Engineer with Asahi Kasei discusses the benefits of inline buffer formulation and presents performance data on the MOTIV^® inline buffer formulation system with case studies demonstrating the flexibility of MOTIV to create a wide variety of complex buffers.

The MOTIV system was originally launched in 2007 as IBD (Inline Buffer Dilution) and has since undergone several modifications and enhancements. In 2013, it evolved into a standard 3 pump system, with further improvements in 2015, including the addition of a reagent tracker for better chemical tracking. Subsequent upgrades in 2016 introduced a five pump system, and in 2018, larger custom units with six and seven pumps were developed. In 2020, IBD was officially renamed MOTIV, and in 2023, a single-use version of the system was launched to eliminate the need for SIP/CIP procedures.

Biopharmaceutical Manufacturing: Strategies for Navigating Raw Material and Process Changes

Change in inevitable, especially in biopharmaceutical manufacturing. The biopharmaceutical industry is constantly evolving with advancements in processing technologies and raw materials providing continuous improvement opportunities for manufacturers to increase efficiency, reduce costs, and mitigate risks while maintain product quality and safety across a product’s lifecycle. That said, raw materials like chromatography resins used in downstream biopharmaceutical manufacturing of regulated products are subject to strict oversight. Any changes made to the manufacturing process must be carefully evaluated using both science- and risk-based approaches and reported to regulatory authorities to ensure the safety and quality of the final product is not affected…

Advancements in Buffer Management and Single Use Inline Buffer Formulation

In this podcast, we spoke with Nainesh Shah, Senior Application Engineer at Asahi Kasei Bioprocess about buffer management including the benefits of inline buffer formulation, and single use inline buffer formulation systems.

We started the podcast by talking about how critical buffer management is to bioprocessing. Mr. Shah discussed how buffers are required in large quantities during the biomanufacturing process and that traditionally buffers were made in large tanks, stored, and used as needed. However, now real estate in the bioprocessing industry is at a premium and companies are looking to utilize new technologies that can reduce facility footprint. For buffer management, it makes sense to create buffer on demand to reduce the footprint dedicated to buffer production in the past.  

Cytiva™ Protein Select™ Resin – A new affinity resin for recombinant proteins

Cytiva™ Protein Select™ resin is an affinity chromatography resin for purifying recombinant proteins using the self-cleaving Cytiva™ Protein Select™ tag. This technology simplifies tagged protein purification when used in research and standardizes purification during process development and later phases of any protein that does not have an affinity binding partner.